CCNU (lomustine), idarubicin and dexamethasone (CIDEX): an effective oral regimen for the treatment of refractory or relapsed myeloma

Autor:	M. Boots, R. Parameswaran, T. J. Littlewood, Stephen M. Kelsey, Diana Samson, M. J. Mills, Chrissy Giles
Rok vydání:	2000
Předmět:	medicine.medical_specialty Chemotherapy medicine.drug_class business.industry medicine.medical_treatment Hematology Lomustine Neutropenia medicine.disease Gastroenterology Surgery Regimen Refractory Internal medicine medicine Corticosteroid Idarubicin business Survival rate medicine.drug
Zdroj:	British Journal of Haematology. 109:571-575
ISSN:	0007-1048
DOI:	10.1046/j.1365-2141.2000.02082.x
Popis:	We report the results of a non-randomized pilot study of an oral regimen comprising CCNU (lomustine; 25 or 50 mg/m2 on day 1), idarubicin (4-demethoxydaunorubicin) (10 mg/m2 on days 1-3) and dexamethasone (10 mg b.d. on days 1-4) in patients with relapsed or refractory myeloma. Treatment was given every 28 d for a maximum of six courses. Sixty patients were entered of whom 57 were evaluable. Overall response rate (partial or minor response) was 49% with 30% of patients achieving a partial response (50% tumour reduction). Response rates were higher in patients with untested relapse than in those with refractory disease (overall response rates 56% vs. 31%). The major toxicity was neutropenia and the regimen was otherwise well tolerated. The median survival from entry of all patients was 15 months, with 30% of patients alive at 2 years. This regimen represents a useful addition to available treatment options.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ea8b6606ad75e77542a4b343f0636842 https://doi.org/10.1046/j.1365-2141.2000.02082.x Zobrazit plný text záznamu Plný text